Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F13%3A00422658" target="_blank" >RIV/68378050:_____/13:00422658 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1186/1471-230X-13-155" target="_blank" >http://dx.doi.org/10.1186/1471-230X-13-155</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/1471-230X-13-155" target="_blank" >10.1186/1471-230X-13-155</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

Popis výsledku v původním jazyce

Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and other cholestatic conditions. Although much has been learned about the molecular basis of the disease pathophysiology, our understanding of the effectsof UDCA remains unclear. Possibly underlying its cytoprotective, anti-apoptotic, anti-oxidative effects, UDCA was reported to regulate the expression of TNF alpha and other inflammatory cytokines. However, it is not known if this effect involves also modulation of ADAM family of metalloproteinases, which are responsible for release of ectodomains of inflammatory cytokines from the cell surface. We hypothesized that UDCA modulates ADAM17 activity, resulting in amelioration of cholestasis in a murine model of bile duct ligation (BDL). UDCA decreases amount of shed TNF alpha, TGF alpha, and sMet in cell culture media and the phosphorylation of ERK1/2. These effects are mediated by the reduction of ADAM17 activity in PMA stimulated cells al

Název v anglickém jazyce

Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

Popis výsledku anglicky

Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and other cholestatic conditions. Although much has been learned about the molecular basis of the disease pathophysiology, our understanding of the effectsof UDCA remains unclear. Possibly underlying its cytoprotective, anti-apoptotic, anti-oxidative effects, UDCA was reported to regulate the expression of TNF alpha and other inflammatory cytokines. However, it is not known if this effect involves also modulation of ADAM family of metalloproteinases, which are responsible for release of ectodomains of inflammatory cytokines from the cell surface. We hypothesized that UDCA modulates ADAM17 activity, resulting in amelioration of cholestasis in a murine model of bile duct ligation (BDL). UDCA decreases amount of shed TNF alpha, TGF alpha, and sMet in cell culture media and the phosphorylation of ERK1/2. These effects are mediated by the reduction of ADAM17 activity in PMA stimulated cells al

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Gastroenterology

ISSN

1471-230X

e-ISSN

—

Svazek periodika

13

Číslo periodika v rámci svazku

30.10.2013

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1

Strana od-do

155-155

Kód UT WoS článku

000328475700001

EID výsledku v databázi Scopus

—